NK1 antagonists

A method for treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of at least one compound of Formula I:

• or a pharmaceutically-acceptable salt thereof, wherein
• Ar1 is phenyl;
• X2 is —O—;
• R1 and R2 are each independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C3alkyl), C3-C8 cycloalkyl, —CH2F, —CHF2 and —CF3;
• or R1 and R2, together with the carbon atom to which they are both attached, form a C3 to C6 alkylene ring;
• or R1 and R2, together with the carbon atom to which they are both attached, form a C═O group;
• R3 is selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C3 alkyl), C3-C8 cycloalkyl, —CH2F, —CHF2 and —CF3;
• each R6 is independently selected from the group consisting of H, C1-C6 alkyl and —OH;
• each R7 is independently selected from the group consisting of H and C1-C6 alkyl;
• n2 is 2;
• R4 and R5, together with the carbon atom to which they are both attached, form a 5- or 6-membered heterocycloalkyl ring selected from the group consisting of:
• wherein said 5- or 6-membered heterocycloalkyl ring is optionally substituted with from 1 to 6 substitutents independently selected from the group consisting of R30 and R31;
• R18 is H, C1-C6 alkyl, C3-C8 cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, hydroxy(C2-C6)alkyl or —P(O)(OH)2;
• R30 and R31 are each independently selected from the group consisting of H and C1-C2 alkyl, or
• R30 and R31, together with the carbon atom to which they are both attached, form ═O;
• R32 and R33 are each independently selected from the group consisting of H and C1-C6 alkyl;
• or a,
• where the physiological disorder, symptom or disease is asthma, emesis, nausea, depression, anxiety, cough or migraine.